Name: Levosimendan
Brand: Selleck Chemicals
SKU: S2446
Availability: InStock
Rating: 5 (2 reviews)

Jump to

Quality Control

Batch: Purity: 99.95%

99.95

Related Targets	CFTR CRM1 CD markers AChR Sodium Channel Potassium Channel GABA Receptor TRP Channel ATPase GluR
Other Calcium Channel Inhibitors	Bay K 8644 Tetrandrine Nilvadipine Flunarizine 2HCl Cilnidipine YM-58483 (BTP2) Ionomycin Imperatorin Manidipine 2HCl Astragaloside A

Solubility

In vitro
Batch:

DMSO : 56 mg/mL (199.8 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	5.000mg/ml (17.84mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to make it clear; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	280.28	Formula	C₁₄H₁₂N₆O	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	141505-33-1	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	OR1259,OR1855,Simsndan			Smiles	CC1CC(=O)NN=C1C2=CC=C(C=C2)NN=C(C#N)C#N

Mechanism of Action

Targets/IC₅₀/Ki	Cardiac troponin C
In vitro	Levosimendan is a calcium sensitizer acting through calcium-dependent binding to cardiac troponin C (cTnC). This compound at 3 μM decreases the value of Ca50 from 2.73μM to 1.19 μM. It exhibits its calcium sensitizing effect through calcium-dependent binding to the N-terminal domain of cTnC. This chemical significantly hyperpolarizes resting potential of rat mesenteric arterial myocytes with an EC50 of 2.9 μM and maximal effect (19.5 mV) at 10 μM, probably through activation of a glibenclamide-sensitive K⁺ channel. It has inotropic and lusitropic actions in failing human myocardium, with average maximum increase in twitch tension of 47% at a levosimendan concentration of 0.8 μM. This compound causes rapid dose-dependent improvement in hemodynamic function in patients with decompensated heart failure.
In vivo	Levosimendan at low concentrations (0.03 to 0.1 μM) acts preferably as a Ca2+ sensitizer, whereas at higher concentrations (0.1 to 0.3 μmol/L) its action as a phosphodiesterase inhibitor contributes to the positive inotropic effect.
References	[1] https://pubmed.ncbi.nlm.nih.gov/8523447/ [2] https://pubmed.ncbi.nlm.nih.gov/9314042/ [3] https://pubmed.ncbi.nlm.nih.gov/9815868/ [4] https://pubmed.ncbi.nlm.nih.gov/11056096/ [5] https://pubmed.ncbi.nlm.nih.gov/7788868/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04705337	Not yet recruiting	Heart Failure New York Heart Association Class III\|Heart Failure New York Heart Association Class IV\|Heart Failure Systolic\|Heart Failure With Reduced Ejection Fraction	Medical University of Bialystok\|Medical Research Agency Poland\|University of Opole\|Medical University of Lodz\|Poznan University of Medical Sciences\|Nicolaus Copernicus University\|National Institute of Cardiology Warsaw Poland\|John Paul II Hospital Krakow\|Azienda Ospedaliera dei Colli	January 1 2021	Phase 4
NCT04252404	Completed	Acute Heart Failure	Arcothova	February 3 2020	--
NCT05076864	Recruiting	Pharmacokinetics\|Metabolites\|Intensive Care\|Renal Failure\|Acute Kidney Injury	Karolinska Institutet\|Karolinska University Hospital	January 1 2020	--
NCT04323709	Completed	Cardiogenic Shock\|Refractory Shock	Hospices Civils de Lyon	January 1 2019	--
NCT03681379	Unknown status	Acute Heart Failure	Nantes University Hospital	October 1 2018	--

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Levosimendan Calcium Channel chemical

Chemical Structure

Molecular Weight: 280.28